Marken Appoints New Vice President, Global Quality Assurance

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2018 /PRNewswire/ -- Marken is pleased to announce the appointment of Navnit Patel, Ph.D., as Vice President, Global Quality Assurance, effective March 05, 2018. Dr. Patel will focus on enhancing Marken's industry-leading quality systems and set new standards for the movement and storage of clinical trial materials.  Marken's ongoing quality initiatives include: implementation of a recently updated Quality Management System (QMS), expansion of the company's own Good Distribution Practice (GDP) certification program, and adding increased capabilities to its electronic document management system.  These quality initiatives are designed to complement the systems and standards of Marken's pharmaceutical clients and are expected to establish new standards for quality in the clinical trial logistics industry. 

During his 23-year career, Dr. Patel served in various quality management positions with leading global pharmaceutical and biotech companies, including: DuPont-Merck, Bristol Myers Squibb, DSM, Schering Plough, Merck, Johnson & Johnson, Novartis, and most recently as Director of Quality Assurance & Quality Control for Rutgers University Cells and DNA Repository-Infinite Biologics.  Dr. Patel holds a Ph.D. in Organic Chemistry, has published over 20 research papers in internationally recognized journals and is a certified Lean Six Sigma Black Belt.

Wes Wheeler, Chief Executive Officer, commented, "Navnit is a seasoned quality leader who brings to Marken a wealth of experience, energy and expertise in pharmaceutical quality assurance, quality control and quality systems management. We are excited to have Navnit join our management team and look forward to his leadership as we take our quality management systems to a whole new level."

About Marken
Marken is a wholly owned subsidiary of UPS. Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments and offers a state-of-the-art GMP-compliant depot network and logistic hubs in 47 locations worldwide for clinical trial material storage and distribution. Marken's more than 830 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the pharma and logistics industry.

SOURCE Marken

Related Links

http://www.marken.com